Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.

Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.

Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.

Abstract: Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.

Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.

Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.

Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.

Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.

Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.

Abstract: Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.